- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB appoints Eva Lindskog as new CEO | 1 | Cision News | ||
| 17.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order for 22,6 MSEK from Returning Customer | 2 | Cision News | ||
| 15.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 7 of 11 | 1 | Cision News | ||
| 06.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order for 8,9 MSEK from Returning Customer | 1 | Cision News | ||
| 01.07. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the seventh exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 1 | Cision News | ||
| 01.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB - Business Update second quarter 2026 | 1 | Cision News | ||
| 04.06. | BIO-WORKS TECHNOLOGIES AB: Resolutions passed at Bio-Works Technologies' annual general meeting 2026 | 1 | Cision News | ||
| 13.05. | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports first quarter 2026 | 2 | Cision News | ||
| BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 29.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives order for WorkBeads 40S from contract manufacturer in Europe | 1 | Cision News | ||
| 17.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 6 of 11 | 8 | Cision News | ||
| 10.04. | BIO-WORKS TECHNOLOGIES AB: Proposed New Board Members in Bio-Works | 1 | Cision News | ||
| 01.04. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the sixth exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 3 | Cision News | ||
| 01.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB - Business Update first quarter 2026 | 13 | Cision News | ||
| 06.03. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB publishes Business Update ahead of next value creation phase | 15 | Cision News |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HELIX BIOPHARMA | 0,940 | -0,53 % | Helix BioPharma Corp (2): Helix BioPharma appoints Loeffler as CMO | ||
| DAMORA THERAPEUTICS | 30,350 | +0,13 % | Damora Therapeutics, Inc.: Damora Announces Redomestication from Delaware to Cayman Islands | BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders... ► Artikel lesen | |
| MODERNA | 113,70 | -0,37 % | BREAKING: AKTIONÄR-Depotwert Moderna explodiert! | Ein Durchbruch der mRNA-Technologie im Bereich der Onkologie: Moderna und der Entwicklungspartner Merck & Co haben die lang ersehnten ersten Ergebnisse der Phase-3-Studie INTerpath-001 mit Intismeran... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 39,640 | -0,05 % | Kaum zu fassen: Die unglaubliche Biotech-Story von Amylyx Pharmaceuticals | Der Biotech-Sektor ist immer wieder für faustdicke Überraschungen gut - sowohl negativ als auch positiv. Bei Amylyx Pharmaceuticals gibt es am Dienstag keine zwei Meinungen: Die Aktie des Biotech-Unternehmens... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 78,47 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| QIAGEN | 38,735 | +3,05 % | DAX Gewinner am Mittwoch: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| BIONTECH | 94,80 | -0,16 % | Schlafender Biotech-Riese vor der nächsten Wachstumsphase? BioNTech, Emyria und die neue Macht der Datenplattformen | ||
| PRAXIS PRECISION MEDICINES | 364,38 | -0,05 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook | ||
| APOGEE THERAPEUTICS | 134,78 | +0,02 % | AbbVie schließt Anleiheemission über 8,0 Mrd. US-Dollar zur Finanzierung der Übernahme von Apogee Therapeutics ab | ||
| NURIX THERAPEUTICS | 27,050 | 0,00 % | Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX | SOUTH SAN FRANCISCO (dpa-AFX) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,760 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,360 | +0,04 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 12,430 | 0,00 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| COGENT BIOSCIENCES | 35,310 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 59,02 | +0,17 % | Barclays startet Coverage für Enliven Therapeutics mit "Overweight" und Kursziel von 78 Dollar |
BIO-WORKS TECHNOLOGIES AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +5,93 % bei einem Aktienkurs von 0,286 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIO-WORKS TECHNOLOGIES AB finden Sie auf Wallstreet Online.